½ðÄê»á¡¤(jinnianhui)½ð×ÖÕÐÅÆ³ÏÐÅÖÁÉÏ-Gold Annual Meeting


»¶Ó­À´µ½ÉϺ£Í¨Îµ£¡

021-54845833/15800441009

Æ·Öʱ£Ö¤ ¡¤ ͨεÊÔ¼Á

µ±Ç°Î»ÖÃ: Ê×Ò³ > ¿ÆÑвúÆ· > ¿ÆÑп¹Ìå > Ò»¿¹ > СÊó¿¹CCAR2µ¥¿Ë¡¿¹Ìå

²úÆ·ÖÐÐÄ

×îвúÆ·

  • СÊó¿¹CCAR2µ¥¿Ë¡¿¹Ìå

    ¹æ¸ñ£º
    ¼Û¸ñ£º£¤
    • Æ·ÅÆ : ͨεÉúÎï
    • Ŀ¼ºÅ : TW6535
    • Ó¦Óà : ½öÏÞÓÚ¿ÆÑÐʹÓÃ
    • »õÆÚ : ÏÖ»õ
    • ¹æ¸ñ £º100ul
  • ÉÌÆ·ÏêÇé
  • ²Î¿¼ÎÄÏ×
  • ˵Ã÷ÊéÏÂÔØ
  • ÉÌÆ·ÆÀÂÛ0
  • Ïà¹Ø²úÆ·

ÖÐÎÄÃû³Æ£ºÐ¡Êó¿¹CCAR2µ¥¿Ë¡¿¹Ìå

Ó¢ÎÄÃû³Æ£º Anti-CCAR2 mouse monoclonal antibody

±ð      Ãû£º cell cycle and apoptosis regulator 2; DBC1; DBC-1; NET35; p30DBC; p30 DBC; KIAA1967

Ïà¹ØÀà±ð£º Ò»¿¹

´¢       ´æ£º Àä¶³£¨-20¡æ£©

ËÞ       Ö÷£º Mouse

¿¹       Ô­£º CCAR2

·´Ó¦ÖÖÊô£º Human, Mouse, Rat, Monkey

±ê  ¼Ç  Î Unconjugate

¿Ë¡ÀàÐÍ£º Mouse Monoclonal

¼¼Êõ¹æ¸ñ

Background:

Core component of the DBIRD complex, a multiprotein complex that acts at the interface between core mRNP particles and RNA polymerase II (RNAPII) and integrates transcript elongation with the regulation of alternative splicing: the DBIRD complex affects local transcript elongation rates and alternative splicing of a large set of exons embedded in (A + T)-rich DNA regions. Inhibits SIRT1 deacetylase activity leading to increasing levels of p53/TP53 acetylation and p53-mediated apoptosis. Inhibits SUV39H1 methyltransferase activity. As part of a histone H3-specific methyltransferase complex may mediate ligand-dependent transcriptional activation by nuclear hormone receptors. Plays a critical role in maintaining genomic stability and cellular integrity following UV-induced genotoxic stress. Regulates the circadian expression of the core clock components NR1D1 and ARNTL/BMAL1. Enhances the transcriptional repressor activity of NR1D1 through stabilization of NR1D1 protein levels by preventing its ubiquitination and subsequent degradation (PubMed:18235501, PubMed:18235502, PubMed:19131338, PubMed:19218236, PubMed:22446626, PubMed:23352644, PubMed:23398316). Represses the ligand-dependent transcriptional activation function of ESR2 (PubMed:20074560). Acts as a regulator of PCK1 expression and gluconeogenesis by a mechanism that involves, at least in part, both NR1D1 and SIRT1 (PubMed:24415752). Negatively regulates the deacetylase activity of HDAC3 and can alter its subcellular localization (PubMed:21030595). Positively regulates the beta-catenin pathway (canonical Wnt signaling pathway) and is required for MCC-mediated repression of the beta-catenin pathway (PubMed:24824780). Represses ligand-dependent transcriptional activation function of NR1H2 and NR1H3 and inhibits the interaction of SIRT1 with NR1H3 (PubMed:25661920). Plays an important role in tumor suppression through p53/TP53 regulation; stabilizes p53/TP53 by affecting its interaction with ubiquitin ligase MDM2 (PubMed:25732823). Represses the transcriptional activator activity of BRCA1 (PubMed:20160719). Inhibits SIRT1 in a CHEK2 and PSEM3-dependent manner and inhibits the activity of CHEK2 in vitro (PubMed:25361978).

Applications:

WB, IF, IP

Name of antibody:

CCAR2

Immunogen:

Fusion protein of human CCAR2

Full name:

cell cycle and apoptosis regulator 2

Synonyms:

DBC1; DBC-1; NET35; p30DBC; p30 DBC; KIAA1967

SwissProt:

Q8N163

WB Predicted band size:

103 kDa

WB Positive control:

COS7, 3T3, C6, Jurkat, A549 and Hela cell lysates

WB Recommended dilution:

500-2000

IF positive control:

Hela cells

IF Recommend dilution:

100-200






¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿
¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿